HIMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hims & Hers Health Inc. (HIMS) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are positive developments such as the Novo Nordisk partnership and analyst upgrades, the financial performance shows declining net income, EPS, and gross margin. Additionally, insider selling has significantly increased, which raises concerns about internal confidence in the stock. The technical indicators and options data do not suggest a strong upward momentum, and there are no proprietary trading signals to support an immediate buy decision. Holding the stock or waiting for more favorable entry points would be more prudent.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 38.726, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. Key support is at $20.741, and resistance is at $24.729. The stock is currently trading near support levels, but there is no strong technical signal for a breakout.
Partnership with Novo Nordisk to sell GLP-1 medications like Wegovy and Ozempic.
Launch of a weight-loss membership program, which could drive revenue growth.
Analyst upgrades and increased price targets, with some seeing significant revenue opportunities from the partnership.
Insider selling has surged by 1967.78% in the past month, indicating potential lack of confidence from company insiders.
Financials show declining net income (-20.84% YoY), EPS (-27.27% YoY), and gross margin (-6.34% YoY).
BofA analysts project a contraction in the GLP-1 franchise by 31% in 2026, raising concerns about future growth.
In Q4 2025, revenue increased by 28.41% YoY to $617.8M, showcasing strong top-line growth. However, net income dropped by 20.84% YoY to $20.6M, EPS fell by 27.27% YoY to $0.08, and gross margin declined by 6.34% YoY to 71.94%. These declines indicate profitability challenges despite revenue growth.
Analysts are mixed but leaning positive. Recent upgrades include price targets raised to $25, $28, $29, and $35, with several firms highlighting the Novo Nordisk partnership as a key growth driver. However, some analysts maintain neutral ratings, citing concerns about higher pricing and potential contraction in the GLP-1 franchise.
